Trial Profile
A Phase 3, Randomized, Double-Blind Trial of Pegylated Liposomal Doxorubicin (PLD) Plus AMG 386 or Placebo in Women With Recurrent Partially Platinum Sensitive or Resistant Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 09 Sep 2019
Price :
$35
*
At a glance
- Drugs Trebananib (Primary) ; Doxorubicin liposomal
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Registrational; Therapeutic Use
- Acronyms TRINOVA-2; TRINOVA-2
- Sponsors Amgen
- 01 Jun 2019 Trial has been completed in UK.
- 08 Dec 2018 This trial has been completed in Italy.
- 18 Jun 2017 This trial has been completed in Belgium.